The Effect of Adjuvant Therapy with Molecular Hydrogen on Endogenous Coenzyme Q10 Levels and Platelet Mitochondrial Bioenergetics in Patients with Non-Alcoholic Fatty Liver Disease.
Zuzana Sumbalová, Jarmila Kucharská, Zuzana Rausová, Anna Gvozdjáková, Mária Szántová, Branislav Kura, Viliam Mojto, Ján Slezák · International journal of molecular sciences · 2023
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In 30 patients with NAFLD and 15 healthy volunteers were included in this clinical trial, after 8 weeks of adjuvant therapy with HRW, the concentration of CoQ10 in platelets increased, plasma TBARS decreased, and the efficiency of OXPHOS improved, while in the P group, the changes were non-significant. These findings add human evidence supporting molecular hydrogen's therapeutic potential across the specific human outcomes evaluated in this study.
What the Findings Mean
H2HUBB reviewed how hydrogen-rich water affected the outcomes measured in 30 patients with NAFLD and 15 healthy volunteers were included in this clinical trial. After 8 weeks of adjuvant therapy with HRW, the concentration of CoQ10 in platelets increased, plasma TBARS decreased, and the efficiency of OXPHOS improved, while in the P group, the changes were non-significant.
What the Researchers Studied
The researchers studied 30 patients with NAFLD and 15 healthy volunteers were included in this clinical trial. The study used a placebo-controlled human clinical trial. The comparison condition was placebo.
What Effects Did Molecular Hydrogen Have?
4 mg/L H₂; approximately 1.32 mg H₂ ingested per reported dose (330 mL hydrogen-rich water); reported treatment duration: 8 weeks. After 8 weeks of adjuvant therapy with HRW, the concentration of CoQ10 in platelets increased, plasma TBARS decreased, and the efficiency of OXPHOS improved, while in the P group, the changes were non-significant. Molecular hydrogen (H₂) has been recognized as a novel medical gas with antioxidant and anti-inflammatory effects.
Why These Findings Matter
These findings add human evidence supporting molecular hydrogen's therapeutic potential across the specific human outcomes evaluated in this study and contribute to the growing body of molecular-hydrogen research.
How Strong Is This Evidence?
This is human clinical evidence from a placebo-controlled human clinical trial. H2HUBB interprets the findings in the context of the study design, sample, comparator, and measured outcomes rather than using one publication as a verdict on hydrogen therapy.
Technical Study Details
H2HUBB classifies this publication as human clinical study with human clinical evidence. The research population or model was 30 patients with NAFLD and 15 healthy volunteers were included in this clinical trial. The reported sample size was 30. The study used a placebo-controlled human clinical trial. The hydrogen delivery method was hydrogen-rich water. The reported hydrogen concentration was 4 mg/L H₂. H2HUBB translates the reported hydrogen dose as approximately 1.32 mg H₂ ingested per reported dose (330 mL hydrogen-rich water). The reported treatment duration was 8 weeks.
Limitations and Safety
No separate limitations or safety findings were identified in the source text available to H2HUBB.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.